C.G. Papaloisou is announcing the introduction of ZANERIL® tablets (enalapril + lercanidipine) for the treatment of hypertension, developed and marketed by the Italian company RECORDATI SpA.
Zaneril is a fixed combination of two established antihypretensive drugs, the ACE-inhibitor enalapril and the calcium channel blocker lercanidipine. Hypertension is an important risk factor for the development of cardiovascular disease and often two or more drugs are required to bring blood pressure under control. Fixed combinations of antihypertensive agents, such as Zaneril, are increasingly used by doctors to achieve the targets set by international guidelines because they are more convinient for patients and help improve their compliance with their treatment.
For more information about Zaneril please click here.